




CellCure
NeuroSciences Ltd.

Cell Cure Ltd., a fully owned subsidiary of BioTime Inc. (CA)., develops and manufactures cell replacement products. The current focus is on retinal degenerative diseases with OpRegen as the leading product for Dry AMD.


The company owns and operates a state of the art GMP manufacturing plant designed for cell based therapeutics.

Direct Differentiation of Embryonic Stem Cells


hESC



Differentiation



**Retinal Pigment Epithelial
Cells**




From culture dish to product-our capabilities

- Expansion of human embryonic stem cells (cell banks)
- Differentiation of hESC to terminally differentiated cell based products.
- Assays Development -in-process, functional, release and characterization.
- Scale up technologies
- In-use implementation in clinical setting


Role of Retinal Pigment Epithelium (RPE) Cells in Dry AMD

- Photoreceptors depend on RPE cells for nourishment, recycling of visual pigment and waste disposal
- When RPE cells die, the photoreceptors also die and central vision is lost

Geographic Atrophy




Degeneration of RPE cells cause dry-AMD.




As RPE cells degenerate photoreceptors lose outer segments and die.

OpRegen -RPE Cell Transplantation Provides a Solution

Transplantation of hESC-derived RPE cells (OpRegen) into the subretinal space



RPE transplantation is a straight forward surgical procedure.



RPE cells in suspension are injected into a bleb formed subretinally.

